Migraine Disorders Clinical Trial
Official title:
Individualized Prediction of Migraine Attacks Using a Mobile Phone App
This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch,
simon@somobilehealth.com 408-981-3814) and Allergan. Mayo Clinic investigators are conducting
the clinical trial, Second Opinion Health is providing the software for use in the trial
(Migraine Alert app for data collection, analysis and machine learning algorithms), and
Allergan is providing funding.
The investigators hypothesize that the use of a mobile phone app and Fitbit wearable to
collect daily headache diary data, exposure/trigger data and physiologic data will predict
the occurrence of migraine attacks with high accuracy. The objective of the trial is to
assess the ability to use daily exposure/trigger and symptom data, as well as physiologic
data (collected by Fitbit) to create individual predictive migraine models to accurately
predict migraine attacks in individual patients via a mobile phone app.
Eliminating migraine attacks before they start is of an enormous importance to migraine
sufferers. But figuring out the onset of an attack before it actually starts remains a major
challenge for the medical community.
The widespread use of mobile smartphones, the availability of wearable devices that measure
health information, and advances in multivariate pattern analysis via machine learning
algorithms allow for development of individual predictive models that can determine the
likelihood of an individual patient developing a migraine on a given day. Such models are
based upon objectively measured biometric parameters (e.g. activity, sleep), objectively
measured environmental conditions (e.g. weather parameters), exposures to possible migraine
triggers, and patient reported symptoms. Using machine-learning algorithms to explore this
large dataset that is collected for each patient, the optimal combination of factors that
most accurately predict the likelihood of a migraine attack is determined.
Prediction of individual migraine attacks would have substantial positive impacts for
patients with migraine. Accurate prediction of a migraine attack would give the migraineur a
greater sense of control over their condition, a sense of control that is often lacking in
patients with migraine. Most importantly, if individual migraine attacks could be predicted
with high accuracy, treatment of that inevitable migraine attack before development of
symptoms could prevent the attack altogether.
Eligible subjects will enter a baseline phase during which subjects will wear a Fitbit device
and record data into the daily headache diary using the mobile phone app. This phase will be
of variable duration for each subject to a maximum of 75 days. It is during the baseline
phase that the individualized predictive model for a migraine attack is developed and
optimized.
During the second phase (75 days), the accuracy of the predictive model will be tested. The
probability of developing a migraine will be calculated and the accuracy of the prediction
will be tested against the patient reported incidence of migraine attacks within the mobile
phone app. Subjects will be blinded to the app's migraine attack predictions to avoid
expectancy bias.
Migraine prediction suffers from 'the curse of dimensionality' (machine learning parlance).
Too many factors affect outcomes, but the outcomes (positive migraine attacks) are few and
far in between. To develop an accurate machine learning model using traditional approaches
requires a long and impractical time duration. Migraine Alert has effectively addressed these
using proprietary algorithms and techniques that generate individual models using fewer
migraines. Covariate analysis is performed for each individual using features derived from
the raw data. Individual models may differ from one other in the specific feature they use
and/or the importance attached to them in the model. Proprietary techniques are used to
create these individual models and to monitor their pre-validation and post-validation
accuracy and recall. Concept drift as evidenced by any degradation in accuracy or recall is
monitored in the prediction phase and model is retrained as necessary.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432379 -
BOTOX® Prophylaxis in Patients With Chronic Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05048914 -
Migraine Abortive Treatment
|
||
Completed |
NCT03662295 -
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
|
||
Completed |
NCT02766517 -
Biomarker Study in Participants With Migraine
|
Early Phase 1 | |
Completed |
NCT00963937 -
Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents
|
Phase 3 | |
Not yet recruiting |
NCT03632928 -
Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
|
||
Completed |
NCT02559895 -
A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
|
Phase 3 | |
Completed |
NCT01435941 -
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
|
N/A | |
Completed |
NCT00743015 -
Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks
|
Phase 1 | |
Completed |
NCT01376141 -
Drug Use Investigation for IMIGRAN Tablet
|
N/A | |
Completed |
NCT02183688 -
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
|
Phase 3 | |
Completed |
NCT06061588 -
"Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"
|
N/A | |
Completed |
NCT03588364 -
The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine
|
N/A | |
Completed |
NCT04091321 -
Association Between Chronic Headache and Back Pain With Childbirth
|
||
Completed |
NCT00385008 -
TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine
|
Phase 3 | |
Active, not recruiting |
NCT05888298 -
Proximal and Distal Approach GON RFT in Migraine
|
N/A | |
Completed |
NCT03435185 -
Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients
|
N/A | |
Recruiting |
NCT06459635 -
Migraine Attack Pain Phase Prediction Study
|
||
Completed |
NCT02565186 -
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
|
Phase 3 |